NEW HAVEN, Conn., Feb. 21 (UPI) -- U.S. scientists have found genetic markers that identify breast cancer subtypes resistant to Herceptin, a primary treatment for HER2-positive breast cancer.The Yale and Harvard universities scientists say their findings could help refine therapy for cancer patients with that class of tumor.>>> Discuss This Story
